Abstract: The present invention relates to the use of a quantity of one or more water-soluble calcium salts and a quantity of glass particles for preparing platelet releasate from a sample of a platelet-rich blood composition obtained from a subject, wherein said quantity of glass particles is from 0.010 g to 0.60 g per ml of said sample and said quantity of the one or more water-soluble calcium salts is from 1.0 ?mol to 12.0 ?mol per ml of said sample. Systems and methods for preparing a platelet releasate are also disclosed, as well as the platelet releasate obtained therefrom and the use thereof in in vitro and in vivo applications.

Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind (as defined herein) Interleukin-6 Receptor (IL-6R), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. In a specific aspect, the present invention provides amino acid sequences and polypeptides that are capable of binding to two or more different antigenic determinants, epitopes, parts, domains of IL-6R, also referred to as “multiparatopic” (such as e.g. “biparatopic” or “triparatopic”, etc.) amino acid sequences and polypeptides.

Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind (as defined herein) Interleukin-6 Receptor (IL-6R), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. In a specific aspect, the present invention provides amino acid sequences and polypeptides that are capable of binding to two or more different antigenic determinants, epitopes, parts, domains of IL-6R, also referred to as “multiparatopic” (such as e.g. “biparatopic” or “triparatopic”, etc.) amino acid sequences and polypeptides.

Abstract: The current invention relates to the field of hypoxia-induced disorders and more specifically to the use of hypoxia inducible factor 2? as a target in a method for the screening for molecules that can be used for the treatment of pulmonary hypertension. The invention further relates to the use of HIF-2? and/or of the HIF-2? inducible protein VEGF for the treatment of neonatal respiratory distress syndrome.

Abstract: The current invention relates to the field of hypoxia-induced disorders and more specifically to the use of hypoxia inducible factor 2? as a target in a method for the screening for molecules that can be used for the treatment of pulmonary hypertension. The invention further relates to the use of HIF-2? and/or of the HIF-2? inducible protein VEGF for the treatment of neonatal respiratory distress syndrome.

Abstract: The current invention relates to the field of hypoxia-induced disorders and more specifically to the use of hypoxia inducible factor 2a? as a target in a method for the screening for molecules that can be used for the treatment of pulmonary hypertension. The invention further relates to the use of HIF-2? and/or of the HIF-2a? inducible protein VEGF for the treatment of neonatal respiratory distress syndrome.